Results 201 to 210 of about 193,078 (253)
Annals of Oncology, 2015 In a phase III trial in patients with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid in reducing skeletal-related events (SREs; radiation to bone, pathologic fracture, surgery to bone, or spinal cord compression).
K N Chi, K N Chi, K Pittman
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacologic Prevention of Skeletal-Related Events in Cancer Patients
Orthopedics, 2010Intravenous bisphosphonates are a standard therapeutic option in the prevention of skeletal-related events in metastatic breast and prostate cancer as well as multiple myeloma with bone involvement. Denosumab represents a new class of medications that inhibits the RANK ligand and is currently being evaluated to prevent skeletal-related events.
Sal, Bottiglieri +2 more
openaire +2 more sources
Managing Bone Metastases and Reducing Skeletal Related Events in Prostate Cancer
Nature Reviews Clinical Oncology, 2014Advanced-stage prostate cancer is associated with skeletal complications related to metastatic disease and its treatment. On the one hand, metastatic disease to bone is commonly associated with skeletal-related events (SREs); on the other hand, treatment with androgen-deprivation therapy (ADT) leads to loss in bone mineral density (BMD) and increased ...
Fred Saad
exaly +3 more sources
Costs of Multiple Myeloma and Associated Skeletal-Related Events in the Netherlands
Expert Review of Pharmacoeconomics and Outcomes Research, 2004Multiple myeloma causes significant skeletal morbidity (e.g., pain and pathologic fractures) resulting from osteolytic lesions, and the associated medical costs can be considerable. Therefore, the authors of this review conducted a retrospective cost analysis to quantify the medical costs associated with skeletal complications in patients treated for ...
Groot, MT (Martijn) +3 more
exaly +3 more sources
Beyond Skeletal-Related Events
European Urology Supplements, 2006Abstract Objectives Zoledronic acid may have potential antitumor activity; it is the most active agent among the bisphosphonates in blocking the prenylation (activation) of small signaling proteins required for cell function and survival. This presentation discusses the results of preclinical studies evaluating the antitumor activity of zoledronic ...
openaire +2 more sources
The Pharmacological Management of Skeletal-Related Events From Metastatic Tumors
Orthopedics, 2009Bone is one of the most common sites of metastatic disease from cancer, affecting around 400,000 patients each year. Skeletal-related events (SRE) include hypercalcemia, fractures, spinal cord compression or severe bone pain and may occur as a complication of metastasis.
Anna, Hitron, Val, Adams
openaire +2 more sources
Managing skeletal related events resulting from bone metastases
BMJ, 2008#### Summary points Pain is one of the most common symptoms managed in a palliative setting, and over half of all metastatic cancers will be associated with pain originating from bone metastases. Breast, lung, and prostate cancers account for about 80% of all bone metastases.1 Management of bone pain is especially important in patients with prostate ...
Anna N, Wilkinson +2 more
openaire +2 more sources
Predicting Skeletal-related Events Using SINS
SpineStudy Design. Predictive study utilized retrospectively collected data. Objective. The primary objective was to evaluate the predictive association between the Spine Instability Neoplastic Score (SINS) and Skeletal-related events (SREs).
Kazuo, Nakanishi +6 more
openaire +2 more sources
Managing cancer-related skeletal events with bisphosphonates
Hospital Medicine, 2004Bone metastases cause considerable morbidity. This article discusses the benefits of bisphosphonates, which are now well established in the treatment of skeletal complications across a wide range of tumour types.
openaire +2 more sources
Update on the Pharmacological Prevention of Skeletal-related Events in Cancer Patients
Orthopedics, 2011Metastases to the bone are a frequent complication of advanced cancer. Bone metastases have been linked to skeletal-related events, which is the composite endpoint used in clinical trials evaluating therapy to minimize these complications. This article discusses bisphosphonates, which are the historical standard for the prevention of skeletal-related ...
Kenneth, Kennedy, Hetalkumari, Patel
openaire +2 more sources